JP2016526385A - モノクローナル抗体の改良された産生方法 - Google Patents

モノクローナル抗体の改良された産生方法 Download PDF

Info

Publication number
JP2016526385A
JP2016526385A JP2016522968A JP2016522968A JP2016526385A JP 2016526385 A JP2016526385 A JP 2016526385A JP 2016522968 A JP2016522968 A JP 2016522968A JP 2016522968 A JP2016522968 A JP 2016522968A JP 2016526385 A JP2016526385 A JP 2016526385A
Authority
JP
Japan
Prior art keywords
temperature
cell culture
antibody
during
glutamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016522968A
Other languages
English (en)
Japanese (ja)
Inventor
クマール メンディラッタ サンジーブ
クマール メンディラッタ サンジーブ
バンディオパディアイ サンジェイ
バンディオパディアイ サンジェイ
パテル サンジェイ
パテル サンジェイ
Original Assignee
カディラ ヘルスケア リミティド
カディラ ヘルスケア リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カディラ ヘルスケア リミティド, カディラ ヘルスケア リミティド filed Critical カディラ ヘルスケア リミティド
Publication of JP2016526385A publication Critical patent/JP2016526385A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2016522968A 2013-07-06 2014-07-07 モノクローナル抗体の改良された産生方法 Pending JP2016526385A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2285/MUM/2013 2013-07-06
PCT/IN2014/000450 WO2015004679A1 (en) 2013-07-06 2014-07-07 Improved process for production of monoclonal antibodies
IN2285MU2013 IN2013MU02285A (enExample) 2013-07-06 2014-07-07

Publications (1)

Publication Number Publication Date
JP2016526385A true JP2016526385A (ja) 2016-09-05

Family

ID=51794933

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016522968A Pending JP2016526385A (ja) 2013-07-06 2014-07-07 モノクローナル抗体の改良された産生方法

Country Status (18)

Country Link
US (1) US20160215319A1 (enExample)
EP (1) EP3019528A1 (enExample)
JP (1) JP2016526385A (enExample)
CN (1) CN105431454A (enExample)
AR (1) AR096839A1 (enExample)
AU (1) AU2014288811B2 (enExample)
BR (1) BR112015032800A2 (enExample)
CA (1) CA2917484A1 (enExample)
EA (1) EA201690171A1 (enExample)
HK (1) HK1218297A1 (enExample)
IL (1) IL243011A0 (enExample)
IN (1) IN2013MU02285A (enExample)
MX (1) MX2016000123A (enExample)
NZ (1) NZ715246A (enExample)
SG (1) SG11201510342VA (enExample)
TW (1) TW201514305A (enExample)
WO (1) WO2015004679A1 (enExample)
ZA (1) ZA201509334B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020188737A (ja) * 2019-05-23 2020-11-26 東ソー株式会社 抗体依存性細胞傷害活性が向上した抗体の製造方法
JP2024536914A (ja) * 2021-10-12 2024-10-08 プレスティージ バイオロジクス カンパニー リミテッド 抗体集団の製造方法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) * 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2017122157A1 (en) * 2016-01-14 2017-07-20 Dr. Reddy’S Laboratories Limited Cell culture process
US20200087390A1 (en) 2016-12-21 2020-03-19 Amgen Inc. Anti-tnf alpha antibody formulations
WO2025160161A1 (en) * 2024-01-23 2025-07-31 Amgen Inc. Methods for modulating monoclonal antibody charge variants

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008511329A (ja) * 2004-08-27 2008-04-17 ワイス・リサーチ・アイルランド・リミテッド ポリペプチドの製造
WO2011079004A1 (en) * 2009-12-23 2011-06-30 Schering Corporation Cell line 3m
WO2011085095A2 (en) * 2010-01-07 2011-07-14 Dr. Reddy's Laboratories Ltd. Enhanced protein expression
JP2013501522A (ja) * 2009-08-11 2013-01-17 ジェネンテック， インコーポレイテッド グルタミンフリー細胞培養培地におけるタンパク質の生産
JP2013524824A (ja) * 2010-04-26 2013-06-20 ノバルティス アーゲー 改良型細胞培養培地

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
WO2002076578A1 (en) * 2001-03-27 2002-10-03 Smithkline Beecham Corporation Control of glycoforms in igg
MY163081A (en) * 2010-12-28 2017-08-15 Chugai Pharmaceutical Co Ltd Animal cell culturing method
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008511329A (ja) * 2004-08-27 2008-04-17 ワイス・リサーチ・アイルランド・リミテッド ポリペプチドの製造
JP2013501522A (ja) * 2009-08-11 2013-01-17 ジェネンテック， インコーポレイテッド グルタミンフリー細胞培養培地におけるタンパク質の生産
WO2011079004A1 (en) * 2009-12-23 2011-06-30 Schering Corporation Cell line 3m
WO2011085095A2 (en) * 2010-01-07 2011-07-14 Dr. Reddy's Laboratories Ltd. Enhanced protein expression
JP2013524824A (ja) * 2010-04-26 2013-06-20 ノバルティス アーゲー 改良型細胞培養培地

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BIOTECHNOLOGY AND BIOENGINEERING, vol. 69, no. 1, JPN6017002649, 2000, pages 74 - 82, ISSN: 0003487715 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020188737A (ja) * 2019-05-23 2020-11-26 東ソー株式会社 抗体依存性細胞傷害活性が向上した抗体の製造方法
JP2024536914A (ja) * 2021-10-12 2024-10-08 プレスティージ バイオロジクス カンパニー リミテッド 抗体集団の製造方法
JP7752445B2 (ja) 2021-10-12 2025-10-10 プレスティージ バイオロジクス カンパニー リミテッド 抗体集団の製造方法

Also Published As

Publication number Publication date
HK1218297A1 (zh) 2017-02-10
AU2014288811B2 (en) 2017-06-08
ZA201509334B (en) 2017-03-29
MX2016000123A (es) 2016-07-14
EA201690171A1 (ru) 2016-06-30
IL243011A0 (en) 2016-03-31
IN2013MU02285A (enExample) 2015-06-19
NZ715246A (en) 2017-07-28
CA2917484A1 (en) 2015-01-15
CN105431454A (zh) 2016-03-23
WO2015004679A1 (en) 2015-01-15
SG11201510342VA (en) 2016-01-28
US20160215319A1 (en) 2016-07-28
TW201514305A (zh) 2015-04-16
AU2014288811A1 (en) 2016-01-28
BR112015032800A2 (pt) 2017-07-25
EP3019528A1 (en) 2016-05-18
AR096839A1 (es) 2016-02-03

Similar Documents

Publication Publication Date Title
AU2014288811B2 (en) Improved process for production of monoclonal antibodies
JP6982578B2 (ja) 細胞培養培地
KR101591671B1 (ko) 항체의 이질성을 감소시키는 방법 및 그 항체의 제조방법
RU2592680C2 (ru) Способ снижения накопления лактата при культивировании и способ получения антитела
JP2021107459A (ja) タンパク質産物の等電性プロファイルをシフトさせる方法およびその使用
JP6674028B2 (ja) モノクローナル抗体組成物中のアフコシル化種の調節
CN107760651A (zh) 一种细胞培养基及生产蛋白质的方法
JP2017516484A (ja) タンパク質生産のための細胞培養工程
CN106222129A (zh) 一种提高抗体纯度的细胞培养基和培养方法
EP3455363A1 (en) Methods for modulating protein galactosylation profiles of recombinant proteins using peracetyl galactose
JP2019500878A (ja) モノクローナル抗体組成物中の高分子量種、酸性荷電種、及び断片の低減
EP3275998A1 (en) A cell culture medium and methods for enhancing recombinant antibody purity
JP2018533365A (ja) 組換えタンパク質の生産プロフィールの調節方法
JP2018531619A (ja) 灌流様式において組換えたんぱく質の生産プロファイルを調節する方法
US20230203554A1 (en) Process for reducing unwanted culture byproducts in cell culture medium
KR20160025622A (ko) 단일클론항체의 생산에 대한 개선된 공정
US11186858B1 (en) Methods for increasing biosimilarity
JP7051820B2 (ja) 組換えタンパク質の生産プロファイルを改変するための方法
CN107849525B (zh) 调节重组蛋白生产样态的方法
ES2755425T3 (es) Métodos para modular perfiles de producción de proteínas recombinantes
KR20230109674A (ko) Fab 고 만노스 당형
CN118516439A (zh) 一种提高IgG2B型二硫键异构体比例的方法
WO2016162514A1 (en) Methods for modulating protein glycosylation profiles of recombinant proteins

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20160304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170428

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170801